Guideline: Screening for prostate cancer (Republic of Cyprus): Difference between revisions
m (Update categories.) |
m (Update categories.) |
||
| Line 27: | Line 27: | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | ||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | <span style="display:none">hasCancerType::C00-C97: All cancer types</span> | ||
<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span> | |||
<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span> | |||
<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span> | |||
<span style="display:none">hasCancerType::C40-C41: Bone cancers</span> | |||
<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span> | |||
<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span> | |||
<span style="display:none">hasCancerType::C50: Breast cancer</span> | |||
<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span> | |||
<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span> | |||
<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span> | |||
<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span> | |||
<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span> | |||
<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span> | |||
<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span> | |||
<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span> | |||
<span style="display:none">hasCancerType::D10-D36: Benign tumour</span> | |||
<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span> | |||
<span style="display:none">hasCancerType::unknown</span> | |||
Revision as of 12:12, 6 December 2025
Go back to Republic of Cyprus page
Primary purpose: To outline the risk assessment and recommended procedures for PSA testing to detect prostate cancer.
Sponsor, manager or home institution: Ministry of Health and Health Insurance Organization.
Type of information: This guideline provides risk percentages for prostate cancer based on PSA levels, along with screening recommendations considering age, race, family history, and other factors affecting PSA results. It also includes guidance on when to pursue further diagnostic procedures and highlights the importance of individualized patient-physician discussions. diagnosis, medical procedures, age, screening, check-up examinations.
Cancer Areas of Interest: C60-C63: Male genitalia cancer. Click here to learn more.
Access to information: Click here to access.
